Table 2 Treatment of gastric cancer with ZD6126

From: ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer

  

ZD6126 (100 mg kg−1)

 

Control

Weekly

Daily

Microvessel density # of vessels/HPF

12.0±1.5

10.1±1.2

7.2±1.6a

Proliferating cells # of cells/HPF

16.9±2.5

8.0±1.1b

7.0±1.3a

Apoptotic cells # of cells/HPF

2.0±0.4

10.8±3.7b

15.0±3.0c

  1. TMK-1 was injected into the gastric wall on day 0. Therapy with ZD6126, either once a week (weekly) or 5 × per week (daily), was initiated on day 14. Mice were killed on day 38. Tumours were harvested and tissue sections were stained with antibodies against CD31 to determine the microvessel density, PCNA to determine the cycling cells, or TUNEL to determine apoptotic cells. Measurements are the mean±the standard error, as determined by counting the positive cells in each of five × 200 high-powered fields (HPF) for at least five tumours from each treatment or control group.
  2. aP<0.05.
  3. bP<0.01.
  4. cP<0.001.
Back to article page